

In silico Drug Discovery Workshop

hosted by the NCATS Assay Guidance Manual Program

Wednesday, October 23, 2024 – Thursday, October 24, 2024 ~ Virtual (All times are in ET)

AGENDA: Day 1

11:00 AM **Introductory Comments** Joni Rutter, National Center for Advancing Translational Sciences (NCATS), National Institutes of Health (NIH) Kimberly Sciarretta, Biomedical Advanced Research and Development Authority (BARDA) 11:20 AM **Overview of Workshop Objectives** Sarine Markossian and Alexey Zakharov, NCATS, NIH 11:30 AM **Keynote: Computer-Aided Drug Discovery Then and Now** Martha S. Head (Marti), Amgen Inc. 12:15 PM Lunch 12:45 PM Session 1: Data sourcing for in silico drug discovery Chair: Sarine Markossian, NCATS 15 Years of ChEMBL: Challenges & Opportunities 12:45 PM Barbara Zdrazil, European Bioinformatics Institute (EMBL-EBI) 1:15 PM Protein Data Bank: From Two Epidemics to the Global Pandemic to mRNA Vaccines and **Paxlovid** Stephen K. Burley, Rutgers 1:45 PM **Break** 2:00 PM Session 2: In silico methodologies used in drug discovery Chair: Alexander Tropsha, University of North Carolina Chapel Hill 2:00 PM Cartography-Guided Exploration of (Ultra)Large Chemical Spaces Alexandre Varnek, The University of Strasbourg 2:30 PM Virtual Screening (TBD) Gisbert Schneider. ETH Zürich 3:00 PM Synthesis-Aware Library Design and Optimal Experimental Design Connor W. Coley, Massachusetts Institute of Technology (MIT) 3:30 PM **Physics-Based Modeling in Drug Discovery** John D. Chodera, Memorial Sloan-Kettering Cancer Center 4:00 PM **Break** 4:15 PM Session 3: Applications of in silico methodologies in drug discovery Chair: Morgan Sherer, BARDA 4:15 PM Applying Artificial Intelligence in a Small Drug Discovery Company Sean Ekins, Collaborations Pharmaceuticals, Inc. 4:45 PM The Computational Assay Driven Discovery of a Novel DHODH Inhibitor Series for Malarial Chemoprevention Vicki Feher, Novartis BioMedical Research



Summary of Day 1 and Adjourn

5:15 PM

AGENDA: Day 2

11:00 AM Session 3: Applications of in silico methodologies in drug discovery (continued)

Chair: Morgan Sherer, BARDA

11:00 AM Industrializing Early Drug Discovery at Scale

Marissa Saunders, Recursion Pharmaceuticals

11:30 AM End-to-End Drug Discovery and Development Using Generative Al and Robotics

Alex Zhavoronkov. Insilico Medicine

12:00 PM Lunch

12:30 PM Session 4: Emerging trends in in silico drug discovery

Chair: Alexey Zakharov, NCATS

12:30 PM Understanding the Chameleonicity and Permeability of PROTACs Using Molecular

Dynamics Simulations, Markov Models, and Deep Learning

Bryn Taylor, Johnson & Johnson Innovative Medicine

1:00 PM Data Generation in Support of Computational Drug Discovery

Cheryl H Arrowsmith, University of Toronto

1:30 PM Human-Al-Robot Collaboration to Accelerate Materials and Molecular Discovery

Milad Abolhasani, North Carolina State University

2:00 PM Protein Therapeutics Design (TBD)

David Baker, University of Washington

2:30 PM Break

3:00 PM Panel Discussion: Bridging the gaps in translation

Chair and moderator: Rommie Amaro, University of California San Diego (USCD)

Panelists: Pat Walters, Relay Therapeutics; Russ B Altman, Stanford University; Christopher Austin, GSK; Martha S.

Head (Marti), Amgen Inc.

3:00 PM Introduction to the Session and Challenges Ahead

Rommie Amaro, UCSD

3:20 PM Dangers of Poor Data (TBD)

Pat Walters, Relay Therapeutics

3:40 PM Paying Attention to Attention in Al Generative Models

Russ B Altman, Stanford University

4:00 PM Team Environment for Better Translation (TBD)

Christopher Austin, GSK

4:20 PM Discussion and Q&A

5:00 PM Closing Session: Summary of Discussions and Perspectives on the Challenges Ahead

Alexey Zakharov, NCATS; Alexander Tropsha, UNC Chapel Hill; Rommie Amaro, USCD

5:15 PM Closing Statement and Adjourn